Sanofi (Sanofi) Change In Inventory

: $207 Mil (TTM As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

Sanofi's change in inventory for the quarter that ended in Jun. 2023 was $0 Mil. It means Sanofi's inventory stayed the same from Dec. 2022 to Jun. 2023 .

Sanofi's change in inventory for the fiscal year that ended in Dec. 2023 was $-916 Mil. It means Sanofi's inventory increased by $916 Mil from Dec. 2022 to Dec. 2023 .

Sanofi's Total Inventories for the quarter that ended in Jun. 2023 was $23,434 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sanofi's Days Inventory for the quarter that ended in Jun. 2023 was 436.92.

Inventory Turnover measures how fast the company turns over its inventory within a year. Sanofi's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.42.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sanofi's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.71.

Sanofi Change In Inventory Historical Data

The historical data trend for Sanofi's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

-607.78

-721.41

-403.39

-981.99

-916.03

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Inventory																-	-1,186.05	206.57	-	-

Sanofi Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $207 Mil.

Sanofi (NAS:SNY) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sanofi's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	16462.989	/	6876.49	*	365 / 2
	=	436.92

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sanofi's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	6876.49	/	16462.989
	=	0.42

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sanofi's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	16462.989	/	23342.362
	=	0.71

Sanofi Change In Inventory Related Terms

Thank you for viewing the detailed overview of Sanofi's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.